We focus on compelling targets for significant unmet medical needs where our deep expertise in assay development and enzymology gives us a competitive advantage and where there is a clear experimental path to a lead molecule.

Some of the key criteria for target selection include:

  • Validated molecular target or pathway
  • Opportunity for first-in-class
  • Proprietary and/or enabling assay
  • Good cellular and animal models
  • Potential for companion diagnostic
  • Low clinical barriers
GEF-1 Liver Fibrosis Discovery
GEF-2 Age-related macular degeneration (AMD) Discovery
GEF-3 Cancer (Multiple) Discovery
cGAS Autoimmune
-Systemic Lupus Erythematosus (SLE)
-Aicardi-Goutieres Syndrome (AGS)
Lead Identification